Abstract

BACKGROUND: The aim of this study was to investigate the influence of adenosine triphosphate (ATP)-binding cassette transporter subfamily B member 1 (ABCB1) gene polymorphism on the efficacy of Remifentanil.

MATERIAL AND METHODS: A total of 276 patients undergoing elective surgeries were included to collect general clinical information and detect the polymorphism of ABCB1 rs1045642 using the TaqMan-MGB probe, and they were divided into 3 groups – a genotype AA group, a genotype AG group, and a genotype GG group – based on different genotypes of ABCB1 rs1045642.

RESULTS: The comparisons showed that there were no differences in sex, age, body mass index (BMI), smoking, drinking status, or ASA class among the 3 groups (P˃0.05). The genotype GG group had higher consumption of Remifentanil than the genotype AA group (P˂0.05), but the genotype AG group was not different from the genotype AA and GG groups (P˃0.05). Comparison of the surgery duration revealed no difference among the 3 groups (P˃0.05). The analepsia time, autonomous respiratory recovery time, and orientation recovery time in the genotype GG group were longer than in the genotype AA group (P˂0.05), but the genotype AG group was not different from the genotype AA and GG groups (P˃0.05). There were no differences in adverse reactions among the 3 groups (P˃0.05).

CONCLUSIONS: ABCB1 gene polymorphism can affect the clinical efficacy of Remifentanil.

Keywords: Anesthesia and Analgesia, Polymorphism, Single Nucleotide, Treatment Outcome, ATP Binding Cassette Transporter, Subfamily B, Biomarkers, Pharmacological, Gene Frequency, Middle Aged, Nucleoside Transport Proteins, remifentanil